Highest-materiality recent filing
Director Tamar Howson resigns; CEO Erik Lundgren appointed to board
Tamar Howson resigned from Board and Compensation Committee effective June 29, 2026, due to retirement; no disagreement.
Immunic shareholders approve 6M share increase to equity plan, elect directors, ratify auditor
Amendment to 2019 Omnibus Equity Plan approved, increasing authorized shares by 6,000,000 to total 8,644,887.
Late-breaking poster introduces novel unified endpoint Confirmed Disability Change (CDC) that consistently favored vidofludimus calcium over placebo across three statistical models.
Immunic appoints Erik Lundgren as CEO; Daniel Vitt resigns as CEO but remains on board
Erik Lundgren appointed CEO effective June 1, 2026; previously SVP at Genentech/Roche, led Ocrevus launch.
Immunic appoints Michael W. Bonney as Chair of Board; MS expertise ahead of trial readouts
Michael W. Bonney appointed Chair effective May 16, 2026; Simona Skerjanec transitions from Interim Chair to board member.
Immunic reports Q1 net loss $32.6M; cash $186.6M; Phase 3 MS data by end-2026
Net loss $32.6M ($1.08/share) vs $25.5M ($2.51/share) YoY; R&D expenses $25.6M.
Michael Panzara appointed CMO effective April 24, 2026; base salary $600K, annual bonus target ≥50% of salary, signing bonus $125K.
Immunic announces 1-for-10 reverse stock split effective April 27, 2026
Reverse stock split at 1-for-10 ratio; reduces outstanding shares from ~136M to ~13.6M.
Immunic stockholder votes authorize reverse split at 1-for-10, effective April 27, 2026
Stockholders approved reverse stock split with 57.4M votes for, 12.6M against, 0.6M abstentions.
Immunic CEO Daniel Vitt enters $670,000 retention bonus as board searches for new CEO
Retention bonus of $670,000 payable if Vitt remains employed through 91st day after new CEO hired.
Immunic regains compliance with Nasdaq minimum bid price requirement
Nasdaq notified Immunic on Mar 27, 2026 it regained compliance with minimum bid price rule (Rule 5550(a)(2)).
Immunic appoints Jon Congleton, Mineralys CEO and ex-Teva exec, to Board
Jon Congleton appointed to Board as Class II director effective March 27, 2026; Board size increased from 8 to 9.
Immunic closes $200M private placement; CEO Vitt to transition; Phase 3 MS data by end-2026
Closed oversubscribed private placement of up to $400M; $200M gross proceeds received Feb 17, 2026.
Immunic announces up to $400M private placement and board changes to fund MS trials
Gross proceeds of up to $400M from private placement led by BVF Partners, with $200M from pre-funded warrants at $0.873 each.
Received approval on Jan 5, 2026 to transfer listing from Nasdaq Global Select to Capital Market, effective Jan 7, 2026.
Immunic appoints Nash as CEO of Gliomic subsidiary; updates Vitt's employment terms
Duane Nash to serve as CEO and President of wholly-owned Gliomic Therapeutics effective Jan 1, 2026, with monthly salary of $33,987.
Immunic Q3 2025 net loss $25.6M; cash $35.1M; warns insufficient liquidity for 12 months
Net loss of $25.6M ($0.13/share) vs $24.4M ($0.24/share) in Q3 2024; nine-month loss $77.9M.
Vidofludimus calcium achieved statistically significant 24-week confirmed disability improvement (HR 2.441, p=0.034) in Phase 2 CALLIPER trial in progressive multiple sclerosis.
Immunic Q2 net loss $27M; vidofludimus reduces disability worsening 24% in PMS trial
Net loss of $27.0M ($0.20/share) for Q2 2025 vs $21.4M ($0.21/share) in Q2 2024.
Immunic grants 35M stock appreciation rights to employees and executives at $0.77 strike
Company authorized up to 35M SARs for employees and exec officers; 22,015,000 to exec officers.
Immunic receives Nasdaq notice for non-compliance with $1.00 minimum bid price
On June 27, 2025, Nasdaq notified Immunic that its common stock bid price closed below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).
Immunic shareholders approve 7M share increase in equity plan, elect three Class II directors
Plan amendment increases authorized shares by 7,000,000 to 26,448,871; approved with 32,765,299 for, 10,731,124 against.
Immunic prices $65M underwritten offering of pre-funded warrants and Series A/B warrants
Offering of 86.7M pre-funded warrants plus Series A & B warrants at $0.7499 per unit; proceeds ~$65M.
Immunic announces public offering of warrants and posts extended phase 2 CALLIPER data
Commenced underwritten public offering of pre-funded warrants and Series A (expire Dec 31, 2025) and Series B (5-year) warrants.
Vidofludimus calcium reduced 24-week confirmed disability worsening risk by 20% overall (n=467) vs placebo.
Immunic prices $5.1M registered direct offering of 5.67M shares at $0.90/share
Offering led by Aberdeen Investments; Titan Partners as placement agent.
Immunic's IMU-856 shows dose-dependent GLP-1 increase in celiac trial; preclinical weight loss
Post-hoc phase 1b analysis: dose-dependent GLP-1 increase up to 250% vs placebo; p=0.014 (80mg) and p=0.003 (160mg).
Immunic posts updated corporate presentation; no new material disclosed
Company filed 8-K on Jan 13, 2025, indicating an updated presentation was posted on its website.
Employment agreement effective Dec 16, 2024 for CEO's planned <1 year US relocation; board role at Immunic AG suspended.
Immunic Q3 net loss $24.4M; positive ENSURE futility analysis; cash runway into Q3 2025
Net loss Q3 2024: $24.4M ($0.24/share) vs $22.8M ($0.51/share) in Q3 2023.
IDMC recommended ENSURE-1 and ENSURE-2 continue unchanged; predetermined futility criteria not met.
Immunic hosts MS R&D Day, discusses vidofludimus calcium for relapsing and progressive MS
Immunic held a multiple sclerosis R&D Day on September 10, 2024.
Immunic extends Executive Chairman Dr. Duane Nash's term to Dec 2025 with salary increase
Term of Executive Chairman Duane Nash extended to December 31, 2025 via Addendum No. 6.
Immunic Q2 net loss $21.4M ($0.21/shr); appoints COO/President Tardio, Board member Skerjanec
Net loss of $21.4M for Q2 2024 vs $24.0M Q2 2023; diluted EPS -$0.21 on 101.3M shares.
Immunic appoints ex-Roche neuroscience head Skerjanec to board; 150K options granted
Simona Skerjanec appointed to board effective July 22, 2024 as Class I director until 2027 annual meeting.
Immunic appoints Jason Tardio as COO/President and promotes Werner Gladdines to CDO
Jason Tardio, former Novartis MS franchise head and Biogen exec, appointed COO and President effective July 12, 2024.
Immunic annual meeting: Vitt, Nash elected Class I directors; auditor ratified; say-on-pay approved
Dr. Daniel Vitt elected with 43.6M votes for, 6.3M withheld; Dr. Duane Nash elected with 43.4M for, 6.4M withheld.
Immunic reports Q1 2024 net loss $29.6M; cash extended into Q3 2025 on $240M private placement
Net loss $29.6M ($0.30/share) vs $25.3M ($0.58) in Q1 2023; R&D spend $18.7M, down 18% YoY.
Immunic stockholders approve increase in authorized shares from 130M to 500M at special meeting
Shareholders approved amendment to certificate of incorporation to increase authorized common stock from 130M to 500M shares.
Immunic reports FY2023 net loss of $93.6M; raises $80M in Jan 2024 private placement
Net loss for FY2023: $93.6M ($2.11 per share) vs $120.4M ($3.78 per share) in FY2022.
Immunic announces private placement of up to $240M; first $80M tranche closes Jan 8
First tranche $80M at $1.43/share to close Jan 8, 2024; lead investor BVF Partners.
Immunic extends CEO, CMO, CSO contracts through Dec 2026 with revised compensation
CEO Daniel Vitt: annual salary EUR 565,653, target bonus up to EUR 311,573, term through Dec 31, 2026.
Immunic reports Q3 2023 net loss $22.8M; positive CALLIPER interim NfL data
Net loss of $22.8M ($0.51/sh) for Q3 2023 vs $21.2M ($0.69/sh) in Q3 2022.
Immunic extends Executive Chairman Duane Nash's term to Dec 2024 with salary increase
Term extended from Dec 31, 2023 to Dec 31, 2024.
Immunic reports positive Phase 2 CALLIPER interim data: NfL reduced 22.4% vs placebo in PMS
Vidofludimus calcium lowered serum NfL by 22.4% vs placebo at 24 weeks in overall PMS (p=0.01 post hoc).
Immunic Q2 2023 net loss $24.0M; cash $77.3M funds into Q4 2024
Net loss of $24.0M ($0.54/share) vs $21.9M ($0.72/share) in Q2 2022.
Immunic shareholders elect Rudick and Törnsén, ratify auditor, approve share plan amendment
Dr. Richard Rudick and Maria Törnsén elected to three-year terms with ~19.9M votes for each; ~5.65M broker non-votes.
Immunic Q1 net loss $25.3M; positive phase 1b IMU-856 celiac data; cash $97.1M
Q1 net loss $25.3M ($0.58/sh) vs $20.8M ($0.74/sh); R&D expenses $23.0M up from $17.4M YoY.
Placebo group had 60.3 µm villous height reduction vs. 20.9 µm (80mg) and 22.5 µm (160mg) for IMU-856 (p=0.04) under gluten challenge.
Immunic appoints MS expert Dr. Richard Rudick to Board; Dr. Ossipow to retire at 2023 meeting
Dr. Rudick appointed as Class III director effective April 26, 2023; term ends at 2023 Annual Meeting.
On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the "Company") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.
Simona Skerjanec, who has been serving as Interim Chairperson since February 2026, will transition from Interim Chairperson and continue to serve as a member of the Board.
appointed Michael W. Bonney as Chair of the Board, effective immediately.
Immunic, Inc. (the "Company") appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer of the Company, effective immediately.
On July 24, 2024, Immunic, Inc. (the “Company”) announced the appointment of Simona Skerjanec, M.Pharm, MBA, as a member of the board of directors (the “Board”) of the Company, effective as of July 22, 2024.
appointment of Jason Tardio as Chief Operating Officer and President, effective July 12, 2024.
promotion of Werner Gladdines from Vice President, Program Management & Clinical Development Operations to Chief Development Officer of the Company.
Additionally, on April 26, 2023, Dr. Vincent Ossipow notified the Board that he plans to retire from the Board at the end of his current term and will not stand for re-election at the 2023 Annual Meeting.
On April 27, 2023, Immunic, Inc. (the “Company”) announced the appointment of Dr. Richard Rudick as a member of the Board of Directors (the “Board”) of the Company, effective as of April 26, 2023.
On July 5, 2022, Immunic, Inc. (the “Company”) announced the appointment of Monika Maria Törnsén as a member of the Board of Directors (the “Board”) of the Company, effective as of July 5, 2022.
The Company also announced that current Class III director, Jan Van den Bossche, will be resigning from the Board. The Board accepted Mr. Van den Bossche’s resignation effective July 5, 2022.
On March 10, 2022, Glenn Whaley was appointed Chief Financial Officer ("CFO") of the Company.
Max materiality 0.95 · Median 0.65 · Most common event other_material